The flocks were chronically infected with M. gallisepticum (84% seropositive by ELISA test) and monitored over a 6 month period.
| TRIAL 1 |
Stipkovits, L. & Burch, D. (1994) |
| Flocks chronically infected |
| |
Negative control |
MG vaccinated |
Denagard® (tiamulin)
programme |
| No of hens housed (HH) |
4 670 |
4 500 |
4 302 |
| No of eggs produced |
517 530 |
515 355 |
536 628 |
| No of eggs / HH |
110.8 |
114.5 |
124.7 |
| Laying (%) |
61.6 |
63.6 |
69.3 |
| Hatchability (%) |
75.4 |
77.3 |
83.3 |
| Mortality (%) |
4.3 |
3.5 |
2.1 |
| No of chicks / HH |
83.5 |
88.5 |
103.9 |
| Extra chicks / HH |
- |
5.0 (6%) |
20.5 (24.5%) |
| Projected results over 42 weeks |
| No of chicks / HH |
107 |
113.4 |
133 |
| Extra chicks / HH |
- |
6.4 |
26 |
|
| Trial 1 |
| No. of chicks per month / HH |
 |
For the cost of 0.75g Denagard (AI) 20.5 more chicks were produced demonstrating the limitations of protection offered by killed vaccines and the benefits of the Denagard programme.
Projecting these results over a 42 week laying period an extra 26 chicks are produced for the cost of 1.25g Denagard (AI) over the untreated controls.
| 
